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ABSTRACT 
Objective: To determine and validate of irbesartan and sinensetin simultaneously by liquid chromatography-tandem mass spectrometry (LC-
MS/MS) and application of this method to study a pharmacokinetic interaction of irbesartan and ethanol extract of Orthosiphon stamineus herba in 
rat plasma. 
Methods: The irbesartan and sinensetin were simultaneously extracted from plasma by protein precipitation with acetonitrile. Samples containing 
irbesartan and sinensetin were analyzed by using liquid chromatography-tandem mass spectrometry (LC-MS/MS) with C18
Results: The method was validated according to EMEA guidelines which showed good reproducibility and linearity of 0.99, the lower limit of 
quantification (LLOQ) were 25 ng/ml and 250 ng/ml for irbesartan and sinensatin, respectively. The precision (% CV) values of within-run and 
between-run analysis is 9.3-5.25% and 1.52–5.47% (for irbesartan), 1.52–5.09% and 2.47–9.14% (for sinensetin) whereas the accuracy (% diff) of 
both irbesartan and sinensetin were less than 20%. Stability studies revealed that irbesartan and sinensetin have been stable for 24 h at room 
temperature, 24 h in the autosampler, 3 freeze-thaw cycles, and at least 30 d at-20 
 column Acquity® (100 
mm × 2.1 mm), 1.7 μm particle size column at 40 °C. The gradient system of mobile phase composition was a mixture of acetonitrile and 0.1% formic 
acid (40:60 v/v), which was pumped at a flow rate of 0.3 ml/min. Mass detection was performed on Waters Xevo Triple Quadrupole equipped with 
an electro spray ionization (ESI) source at positive ion mode in the multiple reaction monitoring (MRM) mode. Irbesartan was detected at m/z 
429.1>205.9, sinensetin was detected at m/z 373>342.9 and losartan as an internal standard was detected at m/z 423.05>404.9. 
o
Conclusion: The developed LC/MS-MS method is valid to evaluate irbesartan and sinensetin simultaneous in vitro and showed good selectivity, 
linearity, accuracy, precision, matrix effect, and stability. The method was successfully applied to study the pharmacokinetics interaction of 
irbesartan and Orthosiphon stamineus herba in rat plasma. 
C. The validated method was applied to evaluate 
pharmacokinetic interactions of irbesartan and ethanol extract of Orthosiphon stamineus herba in rat plasma. 
Keyword: Validated method, LC-MS/MS, Drug interaction, Irbesartan, Orthosiphon stamineus 
© 2016 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
 
INTRODUCTION 
Irbesartan is an angiotensin II receptor type 1 antagonist that works 
on the renin-angiotensin-aldosterone system [1]. Sinensetin was one 
of the bioactive marker compounds from Orthosiphon stamineus [2], 
that is used in traditional medicine for diuretic, antidiabetic, 
antihypertensive, anti inflammation and antitumor, antimicrobial 
[3]. Herbs preparation in combination with a synthetic drug taken 
simultaneously may interact with the synergistic effect result or can 
increase the side effect [4]. So the drug level in plasma must be 
measured in order to study the interaction between herb and drug. 
To support clinical investigations, a reliable analytical method with 
adequate sensitivity is necessary. Several HPLC and LC-MS/MS 
methods have been conducted previously for the determination of 
irbesartan in biological sample such as plasma or urine [5,6] but the 
combination of irbesartan and sinensetin simultaneous analysis has 
not been reported. The present study describes a simple, rapid, 
precise, and accurate LC-MS/MS method for determining irbesartan 
and sinensetin in human plasma in vitro and its application in the 
pharmacokinetic study of irbesartan and ethanol extract of 
Orthosiphon stamineus in rat plasma. 
MATERIALS AND METHODS 
Chemicals and reagents 
Irbesartan was obtained from Sigma-Aldrich, Losartan Potassium 
from Ipca Labs Limited, and sinensetin from Chem Facs. Acetonitrile 
and methanol were HPLC-grade and were purchased from Merck. 
The other chemicals and reagents were analytical grade.  
Instrument and chromatographic conditions 
The chromatography was performed on C18
Preparation of standard solutions and quality control samples 
 column Acquity BEH 
(Bridged Ethylene Hybrid) Waters (100 mm × 2.1 mm), 1.7 μm  at a 
temperature of 40 °C. The gradient mobile phase composition was a 
mixture of acetonitrile and 0.1% formic acid (40:60 v/v), which was 
pumped at a flow rate of 0.3 mL/min. Mass spectrometric detection 
was performed on Waters Xevo TQD Triple Quadrupole (Waters, 
Milford, USA) using multiple reaction monitoring (MRM), ESI+ 
Primary stock solutions of irbesartan (1 mg/ml), sinensetin (1 
mg/ml) and losartan potassium (1 mg/ml) were prepared in 
methanol. Then, diluted with methanol to obtain the certain 
concentration. Human plasma calibration standards of irbesartan 
were prepared by spiking an appropriate amount of the working 
standard solutions into drug-free human plasma. The concentration 
range of irbesartan in calibration curve was 25–2000ng/ml and 
Quality Control (QC) samples were prepared at three concentrations 
that were low (75ng/ml), medium (800ng/ml), and high 
(1500ng/ml). The range concentration of sinensetin in calibration 
curve was 250-20000 ng/ml and QC samples were prepared at three 
concentrations low (750ng/ml), medium (8000ng/ml), and high 
(15000 ng/ml). 
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Sample preparation  
150μl of plasma containing certain concentrations of irbesartan and 
sinensetin were added 50μl of the internal standard working solution 
(5μg/ml) vortex-mixed for 30 Sec. Three parts of acetonitrile (400μl) 
were added to the precipitate protein in plasma, vortex-mixed for 2 
min and centrifuged at 10.000 rpm for 10 min. A 5μl aliquot of the 
supernatant was injected into the LC-MS/MS system. 
Validation of method 
The validation parameters were linearity, selectivity, accuracy, 
precision, matrix effect, and stability. The method was validated in 
accordance with EMEA, 2011. 
Pharmacokinetic study  
The male Spraque Dawley rats weighing 200-250 gram were 
acclimatized for two weeks in order to observe their good health and 
suitability. The rats were given 500 mg/kg body weight of ethanol 
extract of O. stamineus orally for six days and on the 7th
The study protocol was approved by The Ethic Committee, Faculty of 
Medicine University of Indonesia with 07/H2. F1/ETIK/2015 
reference number for notice of approval. 
 day were 
given 40 mg/kg body weight of irbesartan orally concomitantt with 
extract. Approximately 400 μl blood samples were collected into 
heparinized tubes via sinus orbitalis at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 8, 12, 
24 and 34 h after drug administration, then centrifuged at 10000 
rpm for 10 min to separate the plasma. The plasma samples were 
stored at-30 ° C prior to analysis.  
RESULTS 
Optimization method  
Mass detection was performed on Waters Xevo TQD equipped with 
electrospray ionization (ESI) source at positive ion mode in the 
multiple reaction monitoring (MRM) modes. The following 
operational parameters of the MS detector were optimized: MS ion 
mode, Precursor and product ions cone and collision energies are 
presented in table 1. Irbesartan was detected at m/z 429.1>205.9, 
sinensetin was detected at m/z 373>342.9 and losartan was used as 
internal standard at m/z 423.05>404.9 
 
Table 1: Result of optimization detection of MS/MS 
Compound Parent (m/z) Daughter (m/z) Cone (V) Collision (V) 
Irbesartan 429.10 206.90 40 24 
Losartan 423.05 404.9 35 11 
Sinensetin 373.00 342.9 50 25 
 
The full spectrum scan was dominated by protonated molecules [M+H]+m/z 429.10 for irbesartan and 373.00 for sinensetin, and the major 
fragmentations observed in each product spectrum were at m/z 206.90 and 342.90 (fig.1 and fig. 2). 
 
 
Fig. 1: Fragmentation of ion mass spectra of irbesartan 
 
 
Fig. 2: Fragmentation ion mass spectra of sinensetin 
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Chromatogram of irbesartan, sinensetin and losartan 
simultaneously is given in fig. 3. The chromatography condition as 
follows: coulom C18 Acquity BEH (1,7 μm, 100 mm × 2.1 mm ), 
with mobile phase acetonitrile: 0.1% formic acid (40:60), gradient 
system, flow rate 0.3 ml/m, detection with ESI+
 
, mode analisis 
MRM (Multiple Reaction Monitoring) at m/z 429.1>205.9 for 
irbesartan, 423.05>404.9 for losartan and 373>342.9 for 
sinensetin, injected volume 5 µl. 
 
Fig. 3: Chromatogram of irbesartan, sinensetin and losartan simultaneously 
 
Validation assay 
Calibration curve and lower limit of quantification (LLOQ) 
The linearity of each calibration curve was determined by plotting 
the peak area ratio (Y) of analyte to internal standard (analyte/IS) 
versus the nominal concentration (X) of irbesartan.  
The calibration curves were linear over the concentration range of 
25-2000ng/ml for irbesartan and 250-20000ng/ml for sinensetin 
with a correlation coefficient of 0.99. The correlation coefficient 
from five replicate calibration curves on different days was more 
than 0.99.  The lower limit of quantification (LLOQ) was 25ng/ml 
(irbesartan) and 250ng/ml (sinensetin) with a coefficient of 
variation of less than 20%. 
Selectivity  
The selectivity was evaluated by analyzing blank plasma sample and 
blank plasma spiked with irbesartan, sinensetin and internal standard 
(losartan). The result showed that there is no interference endogenous 
compound from the blank plasma of the six different sources, whereas 
the % diff both of irbesartan and sinensetin were less than 20%. 
Carry over 
Carry over value after high concentration injection was 2.86% for 
irbesartan and 16.98% for sinensetin from LLOQ response while the 
carry over of internal standard was 0.44%. The value of the carry 
over-fulfilled the acceptance criteria for analyte<20% and for the 
internal standard of<5%. 
 
Table 2: Accuracy and precision of irbesartan 
Analyte Actual concentration Mean measured concentration  Precision Accuracy 
  (ng/ml) (ng/ml)+SD (n=5) (% CV) (% diff) 
within-run LLOQ (25)  22.42±2.09 9.3 (3.52–18.44) 
 QCL (75)  72.52±1.92 2.65 (0.18-6.14) 
 QCM (800)  711.50±37.38 5.25 (5.51–11.41) 
 QCH (1500) 1467.53±47.33 3.23 (7.19–13.52) 
between-run LLOQ (25)  23.03±1.26 5.47 (0.82–19.92) 
 QCL (75)  72.87±2.03 2.79 (4.24–14.71) 
 QCM (800)  712.77±10.83 1.52 (7.87–14.51) 
  QCH (1500) 1424.86±76.52 5.37 (2.87–14.97) 
                                                                              Table 3: Accuracy and precision of sinensetin 
  
Analyte Actual concentration Mean measured concentration  Precision Accuracy 
  (ng/ml) (ng/ml)+SD (n=5) (% CV) (% diff) 
within-run LLOQ (250) 206.67±4.48 2.17 (14.36–19.03) 
 QCL (750) 619.98±9.40 1.52 (14.11–14.97) 
 QCM (8000)  7283.45±370.94 5.09 (4.48–14.47) 
 QCH (15000) 14838.00±677.31 4.56 (4.18–14.52) 
between-run LLOQ (250) 229.11±20.94 9.14 (3.50–19.92) 
 QCL (750) 766.94±42.15 5.49 (2.81–14.56) 
 QCM (8000) 8535.52±210.76 2.47 (0.38–13.97) 
  QCH (15000) 14764.25±629.04 4.26 (0.03–14.36) 
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Precision and accuracy 
Precision and accuracy were calculated by within run and between 
run variation of QC sample in five replicates at four concentrations 
as shown in table 2 and table 3. The precision (% CV) values of 
within-run and between-run analysis is 9.3-5.25%and 1.52–5.47% 
(for irbesartan), 1.52–5.09% and 2.47–9.14% (for sinensetin) 
whereas the accuracy (% diff) of both irbesartan and sinensetin 
were less than 20%. The within-run and between-run precision and 
accuracy values indicate the adequate reliability and reproducibility 
of the method within the analytical range.  
Matrix effect 
Ion increasing effects due to matrix constituents were observed which 
the value of MF on the low concentration (QCL) was 1.13 (irbesartan) 
and 1.06 (sinensetin), whereas the % CV of both irbesartan and 
sinensetin were less than 15%, but there were no significant variations 
in matrix effects between the different blank source. 
Stability test  
The stability test of irbesartan and sinensetin in plasma was 
evaluated under different temperature and storage condition and 
was performed at QCL and QCH in three replicates. The result of 
stability test showed irbesartan and sinensetin have been stable for 
24 h at room temperature, 24 h in the autosampler, 3 freeze-thaw 
cycles, and at least 30 d at-20 ° C (stability data in table 4). 
Application to interaction pharmacokineticcs 
The method described above was successfully applied to 
pharmacokinetics interaction study of irbesartan and ethanol extract 
of O. stamineous (EKK) in five male rats after an oral administration 
of the irbesartan (40 mg/kg) and extract of O. stamineus (500 
mg/kg). The pharmacokinetic profiles are in fig.4 and the result of 
the pharmacokinetic parameter has been summarized in table 5. 
 
 
Fig. 4: The pharmacokinetic profile of irbe (irbesartan) alone 
(n=5) and irbe+EKK (irbesartan plus extract of O. stamineus) 
(n=5) after oral administration in male rats plasma
 
Table 4: Stability of irbesartan and sinensetin 
Stability Actual conc. 
(ng/ml) 
Mean measured conc 
irbesartan (ng/ml)±SD 
(n=3) 
%Diff. Mean measured conc. 
sinenstin (ng/ml)±SD  
(n=3) 
%Diff 
Short term (24 h) QCL 64.00±0.14 14.53-14.87 850.36±13.97 11.32-14.94 
 QCH 1489.68±47.30 4.40-10.16 13978.51±595.1 8.34-14.86 
Autosampler at 28 ° C (24 h) QCL 75.36±5.09  4.18-7.35 850.76±8.99 12.28-14.46 
 QCH 1475.48±34.98 5.71-10.07 13775.16±151.0 12.90-14.77 
Freeze thaw from-30 ° C to 28 ° C QCL 64.81±1.40 11.55-14.65 847.81±13.22 11.11-14.56 
 QCH 1822.55±17.17 12.74-14.85 15491.34±150.4 4.06-12.11 
Long term at-30 ° C (30 d) QCL 64.80±0.95 12.32-14.84 642.60±3.01 13.93-14.73 
  QCH 1363.08±1.26 14.72-14.87 14168.28±339.1 9.63-13.77 
Note: QCL = Quality control low concentration (75 ng/ml for irbesartan and 750 ng/ml for sinensetin), QCH = Quality control high concentration 
(1500 ng/ml for irbsartan and 15000 ng/ml for sinensetin)  
 
Table 5: The parameter pharmacokinetics of irbesartan 
Parameter Irbesartan Irbesartan+Ethanol extract of O. stamineus 
Cmax (ng/ml) 2426.20 4843.25 
Tmax (hr) 1.5 1.5 
T 23.82 1/2  32.07 
AUC t 38609.62 -inf 39683.12 
AUC 79281.92 0-inf 102688.07 
 
DISCUSSION 
To obtain good peak shape and good retention time, several 
combinations of mobile phase and flow rate were investigated. 
Acetonitrile: 0.1% formic acid (40:60) and flow rate 0.3 ml/min with 
the gradient system can separate the analytes with good peak and 
short retention time [fig. 3]. 
Liquid-liquid extraction (LLE) and protein precipitation method 
were performed to extract irbesartan and sinensetin simultaneously 
from plasma. Based on chromatogram and area of irbesartan and 
sinensetin showed that the protein precipitation with acetonitrile is 
better than protein precipitation with methanol and also liquid-
liquid extraction.  
The method has several advantages as compared to the methods 
reported in literature for irbesartan [5,6] such as simple sample 
preparation procedures by protein precipitation, short analysis time 
(5 min per sample), and high sensitivity which rendered for the 
purpose of its application to measure concentration-time profiles for 
interaction pharmacokinetic in rat plasma 
The result of pharmacokinetics parameter showed that the plasma 
concentration of irbesartan and half time in the group combination 
of irbesartan and extract of O. stamineus was higher and longer than 
the group irbesartan alone. According to in vitro study shown, the O. 
stamineous extract is potent inhibitory activity against CYP2C9 with 
IC50 77.5±1.1 µg/ml [9], so the herb-drug interaction mechanism 
may be due to inhibition of CYP2C9, because irbesartan was also 
metabolized by CYP2C9.  
CONCLUSION 
The developed LC/MS-MS method is valid for irbesartan and 
sinensetin simultaneously in vitro and showed good selectivity, 
linearity, accuracy and precision, matrix effect and stability. The 
method is applicable for pharmacokinetic interaction study of 
irbesartan and Orthosiphon stamineus in rat plasma. 
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